Waldencast Goes Dark: The Unraveling of a Beauty SPAC on Wall Street

LONDON – October 15, 2026 — When a publicly traded company decides to sever its ties with the Securities and Exchange Commission, the official corporate communications inevitably cite administrative efficiency and the optimization of capital. But for those who read the underlying signals of corporate maneuvers, the intent is rarely so benign.

Today, Waldencast plc announced it has filed a Form 15 with the SEC, effectively terminating the registration of its Class A Ordinary Shares and Warrants under the Exchange Act. The filing immediately suspends the company's obligations to file periodic and current reports, including the comprehensive Annual Reports on Form 20-F and Current Reports on Form 6-K. Expected to become effective in 90 days, the move follows the company's recent transition to the Pink Limited market of the OTC Markets Group under the tickers MLKMF and MLKWF.

Officially, Waldencast is executing a cost-reduction strategy, eliminating the exorbitant legal and accounting fees associated with maintaining a Nasdaq listing and SEC compliance. Unofficially, the company is pulling the curtain down on one of the most challenging operational periods in its short history, choosing the obscurity of the "Pink Sheets" over the unforgiving glare of Wall Street.

The High Cost of the Public Glare

To understand the "why" behind Waldencast's retreat, one must look past the press release and into the financial filings the company is now so eager to discontinue. Waldencast was conceived as a global beauty and wellness operating platform, a post-SPAC entity designed to acquire and scale high-growth, purpose-driven brands. Its crown jewels were Obagi Medical and Milk Makeup.

However, the public market is a relentless taskmaster that demands predictable, sequential growth—a metric that has recently eluded the company's remaining operations. While 2025 saw a net loss of $229.75 million and persistent material weaknesses in internal controls over financial reporting, the true catalyst for going dark appears in the first half of 2026.

During the first six months of 2026, Milk Makeup—now Waldencast's sole operating brand—experienced a staggering 57.1% decrease in net revenue, dropping to $26.1 million from $60.9 million in the same period the prior year. This collapse in top-line growth was driven by a confluence of retail headwinds: softer consumer demand, elevated inventory levels at key retail partners like Sephora and Ulta Beauty, and a glaring gap in the brand's innovation calendar that saw zero early-summer product launches.

Furthermore, the brand's gross margin contracted severely from 67.3% to 53.7%, battered by $4.2 million in costs associated with customer allowances, returns, and inventory write-offs for its prior-generation products. When a company faces a $94.9 million net loss from continuing operations in a single half-year and is forced to record a $52.3 million non-cash goodwill impairment charge, the quarterly earnings call transforms from a strategic briefing into a public excoriation. Deregistration, in this context, is a defensive shield.

A Strategic Retreat or a Surrender?

The irony of Waldencast's decision to go dark is that the company is arguably in its strongest cash position in years, albeit at the cost of its diversification. On July 30, 2026, Waldencast completed the sale of its highly profitable Obagi Medical business to Bridgepoint for up to $460 million.

This divestiture was a textbook balance sheet rescue. It generated $149.9 million in net cash proceeds and allowed the company to completely wipe out $178.4 million of outstanding indebtedness. As of late August, Waldencast was debt-free and sitting on $138.6 million in cash and cash equivalents.

With the balance sheet stabilized, management is now entirely focused on rehabilitating Milk Makeup, with plans to officially rename the parent entity to Milk Makeup plc. A rebuilt leadership team across creative, finance, marketing, and operations has been tasked with doubling the brand's 2025 revenue over the next five years.

Yet, executing a turnaround of this magnitude requires time, trial, and inevitable error. It requires heavily discounting old inventory, investing aggressively in new product pipelines—like the recent August relaunch of their signature "Sticks" products—and renegotiating retail shelf space. These are messy, margin-diluting maneuvers that public market investors notoriously punish. By filing Form 15, Waldencast's leadership is buying themselves the operational runway to fix the plumbing without having to explain the leaks to Wall Street every ninety days.

The Plight of the Minority Shareholder

While going dark may serve the strategic timeline of management, it fundamentally alters the social contract with retail investors and minority shareholders. The transition to the OTC Pink Limited market is not merely a change of venue; it is a descent into a regulatory void.

The Pink Limited tier is explicitly designed for companies with financial reporting problems, economic distress, or those that simply refuse to make their information public. Companies on this tier do not certify compliance with established reporting standards. For the retail investor who bought into the Waldencast vision during its Nasdaq tenure, the immediate consequences are severe liquidity constraints and valuation discounts.

Without the mandate of SEC disclosures, trading volumes typically plummet. Market makers are less willing to facilitate trades without transparent financial data, leading to widened bid-ask spreads and price volatility. Shareholders are effectively flying blind, reliant on whatever voluntary, unaudited breadcrumbs the company chooses to share on its investor relations website.

The situation is even more precarious for warrant holders. The company's redeemable warrants, now trading as MLKWF, are exercisable for one Class A Ordinary Share at a strike price of $11.50. With the underlying equity relegated to an illiquid, opaque market, the intrinsic and time value of these derivatives is severely compromised. The lack of transparency makes it nearly impossible for warrant holders to accurately model the future prospects or fair value of the underlying shares, leaving them holding instruments that may never realistically be exercised.

The Broader Beauty SPAC Hangover

Waldencast's trajectory is a poignant case study in the broader unraveling of the beauty and consumer brand SPAC boom. During the peak of the special purpose acquisition company frenzy, numerous indie beauty brands were rushed to the public markets, packaged as disruptive platforms capable of infinitely scaling their millennial and Gen Z consumer bases.

However, the reality of the cosmetics industry is that it is inherently cyclical, fiercely competitive, and deeply reliant on fleeting consumer trends. The structural demands of public markets—which require relentless, quarter-over-quarter compounding growth—are fundamentally at odds with the lifecycle of an indie beauty brand, which often requires periods of consolidation, brand repositioning, and inventory rationalization.

Milk Makeup is not an obsolete brand; it retains a strong ethos of self-expression, clean formulations, and a dedicated core following. But it is currently incompatible with the expectations of institutional capital. Waldencast's decision to deregister its securities is a stark admission that the public market was the wrong vehicle for its platform. By retreating to the shadows of the OTC markets, the company is attempting to reclaim the agility of a private enterprise, hoping that silence will provide the necessary cover to rebuild what the public markets nearly tore apart.